Halberd Corporation CEO Letter - Seite 2

With each success, we move closer to our goal - universal disease eradication through our patented extracorporeal methodology.

Our work in the coming quarter will center on elimination of the remaining antigens and inflammatory cytokines associated with the above neurodegenerative diseases and other diseases. As in other industries, our continuing work has been plagued by ongoing supply shortages, resulting in long delays of our planned research and development. We will continue to strive to address these shortages and move to mitigate delays.

STOCK PERFORMANCE
Halberd's fiscal year concluded July 31, 2021. Documentation for the periods prior to the placement of the current management team delayed submission of the appropriate material to the auditors until mid-September 2021. Recent SEC/FINRA actions to delist non-reporting companies have caused a huge demand for auditor services, thereby delaying approval of our financial package. We are doing everything possible to move this along and up-list to OTCQB. The Form 10 drafting has been sourced to an attorney and will be completed once the audit concludes. Listing on additional stock exchanges will be considered once we complete the up-listing on OTCQB.

Q3 OBJECTIVES AND ACCOMPLISHMENTS RECAP

• Establish proof-of concept for eradication of E. Coli via RF and laser as the initial steps toward development of an Alzheimer's Disease treatment. Proof of concept established.
• Conduct further laboratory development, fine tuning, and demonstration of the effectiveness of our application of the extracorporeal capture and removal of disease antigens without the need for metallic nanoparticles. (Details to be provided pending patent application filings). Dedicated prototypes are in the process of manufacture, but testing has been replaced by the ongoing and very promising laser and RF eradication of neurodegenerative disease antigens.
• Launch immune support product to the market. Launched Vita-Shield-Max^TM Immune Support product on our website, www.vitashieldmax.com, and on Amazon.
• Complete application for up-listing HALB to OTCQB index. Pending audit approval.
• Complete application for Halberd Corp.'s listing on one of the Canadian stock exchanges. Pending audit approval and up-listing to OTCQB.

Q4 OBJECTIVES